Joana Carvalho, PhD, managing science editor —

The combination therapy of melflufen (melphalan flufenamide) and dexamethasone continues to be safe and to elicit deep and durable responses in hard-to-treat patients with relapsed or refractory multiple myeloma, top-line data from a Phase 2 clinical trial shows. The findings will support Oncopeptides‘ submission of a…

Belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, continues to show promise when used alone or in combination with other approved therapies to treat people with relapsed or refractory multiple myeloma, according to data from two clinical trials. Findings from both trials — DREAMM-2 (NCT03525678) and DREAMM-6…

Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528, continues to lead to strong and durable responses in all patients with relapsed or refractory disease who are participating in a Phase 1b/2 trial. These findings were announced in an oral presentation, “Update of…

Karyopharm Therapeutics is asking that Xpovio (selinexor) be approved with Velcade (bortezomib) and low-dose dexamethasone to treat people with multiple myeloma after at least one line of therapy. The request was submitted to the U.S. Food and Drug Administration (FDA) in the form of a…

The European Commission (EC) has approved a new under-the-skin (subcutaneous), fixed-dose formulation of Janssen’s Darzalex (daratumumab) for the treatment of adults with multiple myeloma. The approval of the new type of delivery applies to all indications for which the therapy’s original intravenous (into-the-vein) formulation is…

The U.S. Food and Drug Administration (FDA) asked for more information from Bristol Myers Squibb and Bluebird Bio as it considers a request to approve their lead CAR T-cell therapy — idecabtagene vicleucel (ide-cel; bb2121) — for heavily pre-treated patients with multiple myeloma. The agency’s …

Bristol Myers Squibb and Bluebird Bio are seeking U.S. approval of their lead investigational CAR T-cell therapy — idecabtagene vicleucel (ide-cel; bb2121) — for the treatment of heavily pre-treated multiple myeloma. The companies have submitted a biologics license application to the…

The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc), in combination with Pomalyst (pomalidomide) and dexamethasone, to treat adults with relapsed or refractory multiple myeloma who tried at least two prior lines of therapy, including Revlimid (lenalidomide) and a…

Janssen‘s Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone continues to lead to strong and durable responses, and prolong the time until disease worsening in patients with relapsed or refractory multiple myeloma, according to three-year follow-up data from a Phase 3 trial.

Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528 (JNJ-68284528), safely led to early and deep responses in all patients with relapsed or refractory multiple myeloma treated in the first part of a Phase 1/2 trial. These findings were announced in the oral presentation, “Results from CARTITUDE-1:…